Composition containing ergothioneine for delaying aging and Anti-inflammation, preparation method, and use of composition

Abstract

A composition containing ergothioneine for delaying aging and anti-inflammation, comprising the following components in parts by weight: 0.5-10 parts of ergothioneine and 0.5-10 parts of component a. The component a is at least one of β-carotene or astaxanthin. The components have a remarkable synergistic effect, can delay aging and resist skin photoaging, and also have the effects of anti-skin inflammation, and alleviating dermatitis and skin sensitivity and redness.

Description

A kind of anti-aging and anti-inflammatory composition containing ergothioneine and preparation method and use thereof

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to the Chinese patent application filed with the China Patent Office on February 28, 2024, with application number 202410223518.5 and invention name “A composition containing ergothioneine for delaying aging and anti-inflammatory effects, preparation method and use thereof”, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present application relates to the field of medical technology, and in particular to an anti-aging and anti-inflammatory composition containing ergothioneine, a preparation method thereof, and uses thereof. Background Art

[0004] Aging is a natural process characterized by a slowdown in human functions. The appearance of aging is mainly manifested in skin aging, dryness, wrinkles, sagging, etc. Aging is irreversible, but the aging process can be slowed down. Skin aging mainly includes intrinsic aging and exogenous aging. Exogenous aging refers to aging changes in the skin caused by environmental factors. Because it is mainly affected by ultraviolet (UV) radiation, it is also called photoaging. Unlike intrinsic aging, photoaging can be controlled to a certain extent because it is the result of external factors. Photoaging affects areas exposed to the sun, and its clinical characteristics are fine and coarse wrinkles, roughness, dryness, sagging and changes in pigmentation. Over the past few decades, anti-aging strategies have been developed to combat the signs and functional impairments of skin aging.

[0005] Sensitive skin refers specifically to a hyper-reactive state of the skin under physiological or pathological conditions, primarily affecting the face. Clinically, it manifests as subjective symptoms such as burning, stinging, itching, and tightness in response to physical, chemical, or psychological stimuli, accompanied or absent by objective signs such as erythema, scaling, and telangiectasia. Late-night sleep, high stress levels, and improper use of cosmetics are key contributors to sensitive skin. The mechanisms of sensitive skin include impaired skin barrier function, nervous system-mediated discomfort, immune responses triggering multiple symptoms, and vascular dysfunction. These mechanisms are complex and interconnected, with each contributing to a complex overall effect.

[0006] Summary of the Invention

[0007] Therefore, the technical problem to be solved in the present application is to provide an anti-aging and anti-inflammatory composition containing ergothioneine, a preparation method and use thereof.

[0008] To this end, this application provides the following technical solutions:

[0009] An ergothioneine-containing anti-aging and anti-inflammatory composition comprises the following components in parts by weight: 0.5-10 parts by weight of ergothioneine and 0.5-10 parts by weight of component a; component a is at least one of beta-carotene and astaxanthin.

[0010] Optionally, the following components in parts by weight are included: 1.6 parts by weight of thioneine and 1.7 parts by weight of component a.

[0011] Optionally, the composition further comprises the following components in parts by weight: at least one of 50-1000 parts by weight of collagen peptide, 2-200 parts by weight of ceramide, and 5-500 parts by weight of sodium hyaluronate.

[0012] Optionally, the composition further comprises the following components in parts by weight: at least one of 0.5-100 parts by weight of vitamin E, 0.5-200 parts by weight of vitamin C, 5-30 parts by weight of biotin, and 2-200 parts by weight of niacinamide.

[0013] Optionally, the invention further comprises the following components in parts by weight: at least one of 0.01-1 parts by weight of copper oxide and 2-15 parts by weight of zinc citrate.

[0014] Optionally, the invention further comprises the following components in parts by weight: 100-500 parts by weight of glutathione.

[0015] Optionally, the following components are included in parts by weight:

[0016] 1.6 parts by weight of ergothioneine, 1.7 parts by weight of beta-carotene, and 20 parts by weight of ceramide;

[0017] Or, 0.5 parts by weight of ergothioneine, 5 parts by weight of astaxanthin, 635 parts by weight of collagen peptide, and 265 parts by weight of glutathione;

[0018] Or, 10 parts by weight of ergothioneine, 0.5 parts by weight of beta-carotene, 200 parts by weight of ceramide, and 100 parts by weight of vitamin E;

[0019] Or, 10 parts by weight of ergothioneine, 10 parts by weight of beta-carotene, 50 parts by weight of collagen peptide, and 500 parts by weight of glutathione;

[0020] Or, 5 parts by weight of ergothioneine, 5 parts by weight of astaxanthin, 5 parts by weight of sodium hyaluronate, 0.5 parts by weight of vitamin E, and 30 parts by weight of biotin;

[0021] Or, 1 part by weight of ergothioneine, 0.5 part by weight of astaxanthin, 2 parts by weight of ceramide, 200 parts by weight of vitamin C, and 5 parts by weight of biotin;

[0022] Or, 3.2 parts by weight of ergothioneine, 5.36 parts by weight of astaxanthin, 2.6 parts by weight of ceramide, 15 parts by weight of zinc citrate, and 1 part by weight of copper oxide;

[0023] Or, 1.69 parts by weight of ergothioneine, 1.482 parts by weight of beta-carotene, 834 parts by weight of collagen peptide, 42.1 parts by weight of sodium hyaluronate, 27.78 parts by weight of vitamin C, 1.69 parts by weight of vitamin E, and 0.227 parts by weight of copper oxide;

[0024] Or, 8.5 parts by weight of ergothioneine, 10 parts by weight of astaxanthin, 1000 parts by weight of collagen peptide, 126.5 parts by weight of sodium hyaluronate, and 100 parts by weight of glutathione;

[0025] Or, 0.5 weight part of ergothioneine, 0.5 weight part of beta-carotene, 500 weight parts of sodium hyaluronate, 0.5 weight part of vitamin C, 200 weight parts of niacinamide, 2 weight parts of zinc citrate, and 0.01 weight part of copper oxide.

[0026] A method for preparing the ergothioneine-containing anti-aging and anti-inflammatory composition comprises: weighing raw materials according to a formula and mixing them.

[0027] A preparation comprising the ergothioneine-containing anti-aging and anti-inflammatory composition and a preparation-approved carrier;

[0028] Optionally, the preparation forms include liquid preparations and solid preparations;

[0029] Optionally, the pharmaceutical preparation is in the form of injection, tablet, capsule, granule or paste.

[0030] Optionally, the tablet comprises a tablet core and a coating layer disposed on the surface of the tablet core; the tablet core contains the anti-aging and anti-inflammatory composition; the coating layer comprises a transparent coating layer and a colored coating layer from the inside to the outside; the raw materials of the transparent coating layer include 90-100 parts by weight of hydroxypropyl methylcellulose and 0-10 parts by weight of medium-chain triglycerides; optionally, the colored coating layer is a pink coating layer, and the raw material is OPADRY IIPINK coating solution.

[0031] The anti-aging and anti-inflammatory composition containing ergothioneine, the anti-aging and anti-inflammatory composition containing ergothioneine prepared by the preparation method, or the use of the preparation in preparing anti-aging and anti-inflammatory drugs or foods;

[0032] Optionally, use in the preparation of drugs or foods for resisting skin photoaging;

[0033] Optionally, use in the preparation of anti-dermatitis drugs or foods;

[0034] Optionally, the invention can be used for preparing medicines or foods for preventing skin allergy and redness.

[0035] The technical solution of this application has the following advantages:

[0036] 1. the anti-aging, anti-inflammatory composition containing thioneine provided by the application, comprising the following components in parts by weight: thioneine 0.5-10 parts by weight, component a 0.5-10 parts by weight; component a is any one of beta-carotene and astaxanthin; there is significant synergistic effect between the above-mentioned prescriptions, which can delay aging, resist skin photoaging, and also have anti-skin allergy, improve the effect of dermatitis and sensitive skin redness.

[0037] 2. The anti-aging and anti-inflammatory composition containing ergothioneine provided by the application further includes the following components in parts by weight: at least one of 0.5-100 parts by weight of vitamin E, 0.5-200 parts by weight of vitamin C, 5-30 parts by weight of biotin, and 2-200 parts by weight of nicotinamide; the present application has found that after adding any of the above components, the above components have the effect of maintaining and protecting the normal function of the body, and have a significant synergistic effect with the combination of components in the composition, thereby achieving better anti-aging and anti-skin allergy effects.

[0038] 3. The anti-aging and anti-inflammatory composition containing ergothioneine provided in the present application also includes the following components in parts by weight: at least one of 50-1000 parts by weight of collagen peptide, 2-200 parts by weight of ceramide, and 5-500 parts by weight of sodium hyaluronate; the present application has found that after adding any of the above components, the above components are the basic raw materials of the skin, and the combination with the components in the composition has a significant synergistic effect, which can further play a better role in delaying aging and anti-skin allergies.

[0039] 4. The anti-aging and anti-inflammatory composition containing ergothioneine provided by the application also includes the following components in parts by weight: 0.01-1 parts by weight of copper oxide and at least one of 2-15 parts by weight of zinc citrate; the above components have the function of maintaining and protecting the normal function of the body, and have a significant synergistic effect with the combination of components in the composition, thereby achieving better anti-aging and anti-skin allergy effects.

[0040] 5. The anti-aging and anti-inflammatory composition containing ergothioneine provided by the present application also includes the following components in parts by weight: 100-500 parts by weight of glutathione; the combination of the above components and the components in the composition has a significant synergistic effect, achieving better anti-aging and anti-skin allergy effects.

[0041] 6. A preparation provided by the present application, comprising the anti-aging and anti-inflammatory composition containing thioneine, and a carrier allowed by the preparation, wherein the preparation is a tablet, comprising a core and a coating layer arranged on the surface of the core; the core contains the anti-aging and anti-inflammatory composition containing thioneine; the coating layer comprises a transparent coating layer and a colored coating layer from the inside to the outside; the raw material of the transparent coating layer comprises 90-100 parts by weight of hydroxypropyl methylcellulose and 0-10 parts by weight of medium-chain triglycerides; optionally, the colored coating layer is a pink coating layer, and the raw material is OPADRY IIPINK coating solution; The present application has found that the anti-aging and anti-inflammatory composition containing ergothioneine of the present application is pressed into a tablet core and then subjected to conventional colored coating, and black spots are visible in the prepared tablets, affecting the appearance. The present application has further found that before the colored coating layer is coated, a transparent coating layer composed of raw materials including 90-100 parts by weight of hydroxypropyl methylcellulose and 0-10 parts by weight of medium-chain triglycerides is first coated on the tablet core. The transparent coating layer can isolate oxygen and moisture, hinder the reaction of the raw materials, and reduce the generation of black substances. Then conventional colored coating is performed, and no black spots are visible in the obtained tablets. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the following is a brief introduction to the drawings required for use in the specific implementation methods or the description of the prior art. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without any creative work.

[0043] FIG1 is a picture of the tablet prepared in Example 10 of the present application;

[0044] FIG2 is a picture of the tablets prepared in Comparative Example 1 of the present application. DETAILED DESCRIPTION

[0045] The following examples are provided to further better understand the present application, but are not limited to the best implementation mode described herein, and do not limit the content and protection scope of the present application. Any product identical or similar to the present application obtained by anyone under the inspiration of the present application or by combining the features of the present application with other prior arts shall fall within the scope of protection of the present application.

[0046] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in this field can be used. If the manufacturer of the reagents or instruments is not specified, they are all commercially available conventional reagents.

[0047] Table 1

[0048] Note: The above raw materials are all powders.

[0049] Example

[0050] This embodiment provides the formula of embodiment 1-embodiment 11 as follows:

[0051] Table 2, formula

[0052] The preparation method of the above embodiment:

[0053] Weigh the required raw materials according to the above table and mix them evenly.

[0054] Example 11

[0055] This embodiment provides a preparation, comprising the following steps:

[0056] (1) Using any of the anti-aging and anti-inflammatory compositions described in Examples 1 to 10 as active ingredients, conventional processes are used with or without conventional excipients to prepare tablet cores for later use.

[0057] (2) Prepare a transparent coating solution according to the following formula: Coating powder: 95g of hydroxypropyl methylcellulose (HPMC) and 5g of medium-chain triglycerides (MCT); mix the above coating powder with purified water at a mass ratio of 1:5.25 to prepare a transparent coating solution. For the pink coating solution, use OPADRY II PINK coating solution (commercially available).

[0058] (3) Using a coating machine (coating machine BGB-350F Wanshen), first spray the transparent coating liquid evenly on the surface of the tablet core in step (1), and then spray the pink coating liquid. The spraying process parameters are as follows: setting the coating pan speed at 2 rpm-8 rpm; setting the air inlet temperature at 50°C-100°C; setting the spray gun pressure in the drum to 0.3Mpa-0.5Mpa; setting the atomization pressure to 0.3Mpa-0.6Mpa; setting the flattening pressure to 0.3Mpa-0.5Mpa, and finally obtaining tablets. The structure of the tablets includes a tablet core and a coating layer arranged on the surface of the tablet core; the tablet core contains the anti-aging and anti-inflammatory composition; and the coating layer includes a transparent coating layer and a colored coating layer from the inside to the outside.

[0059] The tablets obtained above had a core weight of 1040 mg. After applying a transparent coating layer, the weight was 1053 mg. After applying a pink coating layer, the weight was 1078 mg. Tablets prepared using the composition described in Example 1 as the active ingredient are shown in Figure 1. As can be seen in Figure 1, no black spots are visible on the tablet surface.

[0060] Example 12

[0061] The difference between this example and Example 11 is that the coating powder is 90 g of hydroxypropyl methylcellulose (HPMC) and 10 g of medium-chain triglyceride (MCT). No black spots are visible on the surface of the prepared tablets.

[0062] Example 13

[0063] The difference between this example and Example 11 is that the coating powder is 100 g of hydroxypropyl methylcellulose (HPMC). No black spots are visible on the surface of the prepared tablets.

[0064] Comparative Example 1

[0065] This embodiment provides a preparation, comprising the following steps:

[0066] (1) Using any of the anti-aging and anti-inflammatory compositions described in Examples 1 to 10 as active ingredients, conventional processes are used with or without conventional excipients to prepare tablet cores for later use.

[0067] (2) Select OPADRY II PINK coating solution as the pink coating solution and set aside.

[0068] (3) Using a coating machine (BGB-350F Wanshen), the transparent coating liquid is first evenly sprayed on the surface of the tablet core in step (1), and then the pink coating liquid is sprayed. The spraying process parameters are as follows: setting the coating pan speed at 2 rpm-8 rpm; setting the air inlet temperature at 50°C-100°C; setting the spray gun pressure in the drum to maintain 0.3 MPa-0.5 MPa; setting the atomization pressure at 0.3 MPa-0.6 MPa; setting the flattening pressure at 0.3 MPa-0.5 MPa, and finally obtaining tablets. The structure of the tablets comprises a tablet core and a coating layer provided on the surface of the tablet core; the tablet core contains the anti-aging and anti-inflammatory composition; the coating layer comprises only one colored coating layer; in the obtained tablets, the tablet core weighs 1040 mg, and the weight after providing a pink coating layer on the tablet core is 1078 mg. Taking the active ingredient as the composition in Example 1 as a representative, the prepared tablets are shown in FIG2 . As can be seen from Figure 2, black spots can be seen on the surface of the tablet.

[0069] Experimental Example 1 Anti-light aging experiment

[0070] This experimental example investigates the effect of the composition of the present application on anti-photoaging

[0071] 1. Testing materials

[0072] 1.1. Sample preparation information

[0073] All the examples were prepared with ultrapure water to a 20.0 mg / mL stock solution and stored at -20°C.

[0074] Positive control: Resveratrol, white powder, batch number F2121344, Shanghai Aladdin Biochemical Technology Co., Ltd., stored at -20°C. Prepared with DMSO to a 20.0 mg / mL stock solution, stored at -20°C.

[0075] Experimental Animals

[0076] Zebrafish were reared in aquaculture water at 28°C (water quality: 200 mg of instant sea salt was added to each liter of reverse osmosis water, conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / L CaCO3). They were bred and provided by our company's fish farming center. The experimental animal use license number is: SYXK(Zhejiang)2022-0004. The breeding and management of zebrafish complies with the requirements of the international AAALAC accreditation (certification number: 001458) and the IACUC ethics review number is: IACUC-2023-3719-2-01.

[0077] Wild-type AB strain zebrafish, bred in natural pairs, were used for the evaluation of the anti-photoaging efficacy of the samples. Zebrafish aged 2 days post fertilization (dpf) were used for the evaluation of the anti-photoaging efficacy of the samples.

[0078] 1.3. Instruments, consumables, and reagents

[0079] A dissecting microscope (SZX7, OLYMPUS, Japan); a CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); a precision electronic balance (CP214, OHAUS, USA); a multifunctional microplate reader (SPARK, TECAN, Austria); simulated sunlight (SOL500, Hoenle, Germany); a 96-well microplate (Costar, China); and a 6-well microplate (Zhejiang Bellanbo Biotechnology Co., Ltd., China).

[0080] CM-H2DCFDA (lot number 2456929, Invitrogen, USA); dimethyl sulfoxide (DMSO, lot number BCCD8942, Sigma, Austria); methylcellulose (lot number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China).

[0081] 2. Detection Method

[0082] Wild-type AB zebrafish (2 dpf) were randomly selected and plated in 6-well plates, with 30 zebrafish treated in each well (experimental group). Samples were administered with water (concentrations shown in Table 2), along with a positive control of resveratrol at a concentration of 10.0 μg / mL. A normal control group and a model control group were also established, with the volume per well being 3 mL. Except for the normal control group, all other experimental groups were exposed to sunlight to establish a UV-induced damage model. After 3 days of treatment at 28°C, 8 randomly selected zebrafish from each experimental group were photographed under a dissecting microscope. Data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software. The caudal fin area of ​​the zebrafish was analyzed, and the anti-photoaging efficacy of the samples was evaluated using statistical analysis of this indicator. Statistical results are expressed as mean ± SE. SPSS26.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant. The specific statistical methods were as follows: the independent sample T test in the parameter test was used to compare the samples with the model control group; the parameter test-one-way ANOVA analysis-LSD (with description, fixed and random effects, and mean value graph checked in the options) was used for statistical analysis when comparing samples with each other.

[0083] 3. Test results

[0084] Table 3. Anti-photoaging effect

[0085] *, **, *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively, compared with the model control group. Different letters a to f indicate significant differences at p < 0.05.

[0086] As can be seen from the result of the above table, the photoaging-resistant tail fin area of ​​model control group is significantly lower than that of normal control group, illustrating that model control group is successfully constructed. The photoaging-resistant tail fin area of ​​positive controls, embodiment group and independent raw material thioneine, astaxanthin, ceramide, nicotinamide, glutathione etc. is significantly higher than model control group (p<0.05 or p<0.01), illustrating that positive controls, embodiment group and independent raw material thioneine, astaxanthin, ceramide, nicotinamide, glutathione have the effect of photoaging-resistant. At same concentrations, the photoaging-resistant tail fin area of ​​embodiment group is significantly higher than independent raw material, illustrating that there is significant collaborative photoaging-resistant effect between each component in the composition of the application, further, between embodiment 1-10, compare, the photoaging-resistant effect of embodiment 8 is optimal, embodiment 2-7,9-10 is second, and example case 1 is second.

[0087] Experimental Example 2 Skin Anti-inflammatory Test

[0088] This experimental example investigates the effect of the composition of the present application on skin anti-inflammatory

[0089] 1. Testing materials

[0090] 1.1. Sample preparation information

[0091] All the examples were prepared with ultrapure water to a 20.0 mg / mL stock solution and stored at -20°C.

[0092] Positive control: Dexamethasone, white powder, batch number C2110208, Shanghai Aladdin Biochemical Technology Co., Ltd., stored at 4°C. Prepare a 3.92 mg / mL stock solution in DMSO for immediate use.

[0093] Experimental Animals

[0094] Zebrafish were reared in aquaculture water at 28°C (water quality: 200 mg of instant sea salt was added to each liter of reverse osmosis water, conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / L CaCO3). They were bred and provided by our company's fish farming center. The experimental animal use license number is: SYXK(Zhejiang)2022-0004. The breeding and management of zebrafish complies with the requirements of the international AAALAC accreditation (certification number: 001458) and the IACUC ethics review number is: IACUC-2023-3719-2-01.

[0095] Transgenic neutrophil green fluorescent zebrafish (MPX) were bred by natural pair mating. Zebrafish aged 2 dpf were used to evaluate the anti-inflammatory efficacy of the sample.

[0096] Wild-type AB zebrafish, bred in natural pairs, were used to determine the relative expression of genes with anti-inflammatory properties in the skin of 2-dpf zebrafish.

[0097] 1.3. Instruments, consumables, and reagents

[0098] Dissecting microscope (SZX7, OLYMPUS, Japan); motorized focus continuous zoom fluorescence microscope (AZ100, Nikon, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); precision electronic balance (CP214, OHAUS, USA); fully automatic sample rapid grinding device (JXFSTPRP-24L, Shanghai Jingxin Laboratory Equipment Technology Department, China); high-speed refrigerated centrifuge (Heraeus Fresco17, ThermoFisher, Germany); fully automatic nucleic acid extraction instrument (Auto-Pure32A, Hangzhou Aosheng Instrument Co., Ltd., China); ordinary PCR amplification instrument (T100, BIO-RAD, Singapore); fluorescence quantitative PCR instrument (CFX Connect, BIO-RAD, Singapore); UV-visible spectrophotometer (Nanodrop 2000, Thermo, USA); microplate mini centrifuge (BE-6100, Haimen Qilin Bell Instrument Manufacturing Co., Ltd., China); optical adhesive sealing film B (MSB1001, Bio-rad, USA); low-skirt 96-well plate (transparent) (HSP9601, Bio-rad, USA); 6-well plate (Zhejiang Beilanbo Biotechnology Co., Ltd., China).

[0099] Sodium dodecyl sulfate (Lot No. L212807, Shanghai Aladdin Biochemical Technology Co., Ltd., China); methanol (Lot No. 20220514, Sinopharm Chemical Reagent Co., Ltd., China); dimethyl sulfoxide (DMSO, Lot No. BCCD8942, Sigma, Switzerland); methylcellulose (Lot No. C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); ChamQ Universal SYBR qPCR Master Mix (Lot No. 027E2201CD, Vazyme, China); FastKing cDNA First-Strand Synthesis Kit (Genomic-Free) (Lot No. Y1712, Tiangen Biochemical Technology (Beijing) Co., Ltd., China); Universal RNA Extraction TL Kit C (Cat. No. TL2204001643C, Foshan Aowei Biotechnology Co., Ltd., China).

[0100] 2. Detection Method

[0101] Wild-type AB zebrafish (2 dpf) were randomly selected and plated in 6-well plates, with 30 zebrafish treated in each well (experimental group). Samples were administered with dexamethasone (3.92 μg / mL), a positive control, and a normal control and model control groups, respectively. Each well contained 3 mL of water. Except for the normal control group, all other experimental groups were treated with sodium dodecyl sulfate (final concentration 60 μg / mL) in water to establish a zebrafish skin inflammation model. Three experiments were performed in parallel. After treatment at 28°C for 16 hours, total RNA was extracted from each zebrafish using the Universal RNA Extraction TL Kit C. Total RNA concentration and purity were determined using a UV-Vis spectrophotometer. 2.00 μg of total RNA from each zebrafish sample was synthesized into 20.0 μL of cDNA according to the instructions of the first-strand cDNA synthesis kit. The expression of β-actin and IL-17a / f3 genes was analyzed by q-PCR. β-actin was used as an internal control for gene expression to calculate the relative RNA expression of IL-17a. Statistical results are expressed as mean ± SE. Statistical analysis was performed using SPSS 26.0 software. P < 0.05 indicated statistical significance. The specific statistical methods were as follows: Comparisons between samples and the model control group were performed using parametric tests-one-way ANOVA analysis with Tukey or Dunnett's method. Comparisons between samples were performed using parametric tests-one-way ANOVA analysis with LSD (with descriptive, fixed and random effects, and mean plots selected in the options).

[0102] 3. Test results

[0103] Table 4. Anti-inflammatory effect

[0104] *, **, *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively, compared with the model control group. a, b, c, d, e, and f indicate statistically significant differences between each other at p < 0.05.

[0105] Because IL-17 inflammatory factors, IL-17 secreted by skin immune cells promotes inflammation and accelerates skin aging. Therefore, the expression level of the IL-17a gene will reflect the situation of skin inflammation. High expression of the IL-17a gene reflects high content of skin inflammatory factors, that is, the composition has poor anti-inflammatory effect, and low expression of the IL-17a gene reflects low content of skin inflammatory factors, that is, the composition has excellent anti-inflammatory effect. From the above results, it can be seen that the relative expression of the IL-17a gene in the model control group is significantly higher than that in the normal control group, indicating that the model control group was successfully constructed. Compared with the model control group, the relative expression of the IL-17a gene in the positive control and the example group and the raw material alone is significantly lower than that in the model control group, indicating that the positive control, the example and the raw material alone all have significant skin anti-inflammatory effects. The relative expression of the IL-17a gene in the example group is significantly lower than that in the raw material alone, indicating that there is a significant synergistic effect between the components in the prescription of the example group, which can significantly resist skin inflammation. Furthermore, compared between Examples 1-10, the anti-skin inflammation effect of Example 8 is the best, followed by Examples 2-7 and 9-10, and then Example 1.

[0106] Experimental Example 3: Skin Sensitivity and Redness Experiment

[0107] This experimental example investigates the effect of the composition of the present invention on skin sensitivity and redness.

[0108] 1. Testing materials

[0109] 1.1. Sample Information

[0110] The compositions of each example were mixed with the relevant raw materials according to the formula and then tableted or taken individually. Each tablet contained 1 g of the drug and weighed 1078 mg. The excipients used for tableting were conventional excipients such as microcrystalline cellulose, magnesium stearate, crospovidone, or croscarmellose sodium, and conventional tableting techniques were used.

[0111] 2. Detection Method

[0112] The subjects were healthy Chinese women aged 30 to 55 (volunteers recruited from the public). A doctor determined that redness on the cheeks was an inclusion criterion. Five participants in each group took the drug, three tablets daily, for 28 days. Testing was performed on days 0 and 28, designated D0 and D28, respectively.

[0113] Skin redness intensity was determined by analyzing facial images captured with Visia-CR using Image-Pro Plus software. The redness-sensitivity index was calculated by analyzing the cheek skin a* value in images of the red area under cross-polarized light. Lower values ​​indicate less redness. The skin sensitivity redness level for each group was calculated by subtracting the cheek skin a* value at D28 from the cheek skin a* value at D0.

[0114] The data processing method is: SPSS26.0 software is used for statistical analysis, p < 0.05 indicates that the difference is statistically significant. The specific statistical methods are as follows: compared with the blank control group, the parameter test-one-way ANOVA analysis-Tukey or Dunnett's statistical analysis is used; compared with samples, the parameter test-one-way ANOVA analysis-LSD (check the description, fixed and random effects, and mean value graph in the options) is used for statistical analysis.

[0115] 3.The test results are shown in the table below.

[0116] Table 5: Effects on sensitive skin and redness

[0117] Note: *, **, *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively, compared with the blank control group. a, b, and c indicate statistically significant differences between each other at p < 0.05.

[0118] As can be seen from the table above, the level of skin sensitivity and redness in the Example group was significantly lower than that in the blank control group, indicating that the Example group has a significant effect in reducing skin sensitivity and redness. However, there was no significant difference between the raw material group and the blank control group, indicating that the raw material group alone had no significant effect in reducing skin sensitivity and redness. This also indicates that the components in the Example group have a significant synergistic effect, significantly reducing skin sensitivity and redness. Furthermore, when comparing Examples 1-10, Example 8 has the best anti-skin inflammation effect, followed by Examples 2-7, 9-10, and Example 1.

[0119] Obviously, the above embodiments are merely examples for clarity of explanation and are not intended to limit the implementation methods. Those skilled in the art will readily appreciate that other variations or modifications based on the above descriptions are possible. It is not necessary and impossible to enumerate all implementation methods here. Obvious variations or modifications arising therefrom remain within the scope of protection of the present invention.

Claims

1. An anti-aging and anti-inflammatory composition containing ergothioneine, characterized in that, The invention comprises the following components in parts by weight: 0.5-10 parts by weight of ergothioneine and 0.5-10 parts by weight of component a; component a is at least one of beta-carotene and astaxanthin.

2. a kind of anti-aging, anti-inflammatory composition containing ergothioneine according to claim 1, is characterized in that, The invention comprises the following components in parts by weight: 1.6 parts by weight of thioneine and 1.7 parts by weight of component a.

3. a kind of anti-aging, anti-inflammatory composition containing ergothioneine according to claim 1 or 2, is characterized in that, The invention also includes the following components in parts by weight: at least one of 50-1000 parts by weight of collagen peptide, 2-200 parts by weight of ceramide, and 5-500 parts by weight of sodium hyaluronate.

4. a kind of anti-aging, anti-inflammatory composition containing ergothioneine according to claim 3, is characterized in that, The invention also includes the following components in parts by weight: at least one of 0.5-100 parts by weight of vitamin E, 0.5-200 parts by weight of vitamin C, 5-30 parts by weight of biotin, and 2-200 parts by weight of nicotinamide.

5. a kind of anti-aging, anti-inflammatory composition containing ergothioneine according to claim 3, is characterized in that, The invention also includes the following components in parts by weight: at least one of 0.01-1 parts by weight of copper oxide and 2-15 parts by weight of zinc citrate.

6. a kind of anti-aging, anti-inflammatory composition containing ergothioneine according to claim 3, is characterized in that, The invention also comprises the following components in parts by weight: 100-500 parts by weight of glutathione.

7. according to a kind of anti-aging, anti-inflammatory composition containing ergothioneine described in any one of claim 1-6, it is characterized in that, The composition comprises the following components in parts by weight: 1.6 parts by weight of ergothioneine, 1.7 parts by weight of beta-carotene, and 20 parts by weight of ceramide; Or, 0.5 parts by weight of ergothioneine, 5 parts by weight of astaxanthin, 635 parts by weight of collagen peptide, and 265 parts by weight of glutathione; Or, 10 parts by weight of ergothioneine, 0.5 parts by weight of beta-carotene, 200 parts by weight of ceramide, and 100 parts by weight of vitamin E; Or, 10 parts by weight of ergothioneine, 10 parts by weight of beta-carotene, 50 parts by weight of collagen peptide, and 500 parts by weight of glutathione; Or, 5 parts by weight of ergothioneine, 5 parts by weight of astaxanthin, 5 parts by weight of sodium hyaluronate, 0.5 parts by weight of vitamin E, and 30 parts by weight of biotin; Or, 1 part by weight of ergothioneine, 0.5 part by weight of astaxanthin, 2 parts by weight of ceramide, 200 parts by weight of vitamin C, and 5 parts by weight of biotin; Or, 3.2 parts by weight of ergothioneine, 5.36 parts by weight of astaxanthin, 2.6 parts by weight of ceramide, 15 parts by weight of zinc citrate, and 1 part by weight of copper oxide; Or, 1.69 parts by weight of ergothioneine, 1.482 parts by weight of beta-carotene, 834 parts by weight of collagen peptide, 42.1 parts by weight of sodium hyaluronate, 27.78 parts by weight of vitamin C, 1.69 parts by weight of vitamin E, and 0.227 parts by weight of copper oxide; Or, 8.5 parts by weight of ergothioneine, 10 parts by weight of astaxanthin, 1000 parts by weight of collagen peptide, 126.5 parts by weight of sodium hyaluronate, and 100 parts by weight of glutathione; Or, 0.5 weight part of ergothioneine, 0.5 weight part of beta-carotene, 500 weight parts of sodium hyaluronate, 0.5 weight part of vitamin C, 200 weight parts of niacinamide, 2 weight parts of zinc citrate, and 0.01 weight part of copper oxide.

8. a preparation method of the anti-aging, anti-inflammatory composition containing ergothioneine as described in any one of claims 1-7, is characterized in that, include: Weigh the raw materials according to the recipe and mix them.

9. A preparation, characterized in that An anti-aging and anti-inflammatory composition containing ergothioneine according to any one of claims 1 to 7, and a formulation-allowed carrier; Optionally, the preparation forms include liquid preparations and solid preparations; Optionally, the pharmaceutical preparation is in the form of an injection, tablet, capsule, granule or paste; Optionally, the tablet comprises a tablet core and a coating layer disposed on the surface of the tablet core; the tablet core contains the anti-aging and anti-inflammatory composition; the coating layer comprises a transparent coating layer and a colored coating layer from the inside to the outside; the raw materials of the transparent coating layer include 90-100 parts by weight of hydroxypropyl methylcellulose and 0-10 parts by weight of medium-chain triglycerides; preferably, the colored coating layer is a pink coating layer, and the raw material is OPADRY II PINK coating solution.

10. The anti-aging and anti-inflammatory composition containing ergothioneine according to any one of claims 1 to 7, the anti-aging and anti-inflammatory composition containing ergothioneine prepared by the preparation method according to claim 8, or the preparation according to claim 9 in the preparation of anti-aging and anti-inflammatory drugs or foods; Optionally, use in the preparation of drugs or foods for resisting skin photoaging; Optionally, use in the preparation of anti-dermatitis drugs or foods; Optionally, the invention can be used for preparing medicines or foods for preventing skin allergy and redness.

Images